Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Multiple Myeloma 38Lymphoma, Non-Hodgkin 32Leukemia, Myeloid, Acute 26Hodgkin Disease 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Lymphoma 12Myelodysplastic Syndromes 11Leukemia, Lymphocytic, Chronic, B-Cell 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms, Plasma Cell 6Leukemia 6Recurrence 3Pancreatic Neoplasms 3Lymphoma, Mantle-Cell 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Hematologic Neoplasms 3Gliosarcoma 3Glioblastoma 3Warts 2Sezary Syndrome 2Neutropenia 2Myeloproliferative Disorders 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Large-Cell, Immunoblastic 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, Hairy Cell 2Infections 2Immunologic Deficiency Syndromes 2

Interventions

Cisplatin 258Radiotherapy 193Cetuximab 151pembrolizumab 123Docetaxel 97Fluorouracil 92Carboplatin 80Paclitaxel 78Radiotherapy, Intensity-Modulated 72Surveys and Questionnaires 46Nivolumab 42Drug Therapy 34Radiation 33Blood Specimen Collection 27Erlotinib Hydrochloride 26Gemcitabine 25Immunohistochemistry 22Gefitinib 22Cyclophosphamide 22Surgical Procedures, Operative 21Standard of Care 20durvalumab 19Pemetrexed 19Magnetic Resonance Spectroscopy 19Radiosurgery 17Capecitabine 17Chemotherapy, Adjuvant 16Celecoxib 16Biopsy 16atezolizumab 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Head and Neck Neoplasms × plerixafor × Clear all
NCT04058145 2020-09-07

AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell Carcinoma

Massachusetts General Hospital

Phase 2 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡